ROsuvastatin LOading and Clinical Outcomes Trial

Summary

The aim of the present study was to evaluate the effect of pre-procedural single high loading dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite of death or myocardial infarction from cardiovascular (CV) causes, target vessel revascularization (TVR), or stroke.

Timeline

Start

2008-01

Primary completion

2012-01

Completion

2012-01

Drugs

Indications